Figure 2.

Cantharidin analogs inhibit oral squamous cell carcinoma (OSCC) proliferation. (A) Luminescent adenosine triphosphate (ATP)–based proliferation assays were performed in OSCC cell lines after a 24-h exposure to cantharidin (CNT; IC₅₀, 8.04–28.9), norcantharidin (NOR; IC₅₀ > 100), and cantharidic acid (CAC; IC₅₀, 3.26–15.7). (B) Colorimetric cell viability MTT assays were performed in OSCC cell lines after 24 h of exposure to CNT (IC₅₀, 10.6–11.6) and NOR (IC₅₀ > 100). (C) Luminescent ATP-based proliferation assays performed with A549 parental and Bax/Bak^{–/– –/–, –/–} cells lines after a 24- and 48-h exposure to CNT (2-way analysis of variance, P < 0.0001 for dose and for interaction).